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Abstract
Background: A number of studies have provided strong evidence for the use of cognitive
behavior therapy (CBT) in the treatment of social anxiety disorder (SAD). However, all of the
previous reports were from Europe and North America and it is unknown whether Western
psychological therapies are effective for SAD in non-Western cultures. The present pilot study
aimed to evaluate CBT program for SAD which was originally developed for Western patients,
among Japanese patients.
Methods: Fifty-seven outpatients who participated in group CBT for SAD were evaluated using
eight self-reported and one clinician-administered questionnaires to measure various aspects of
SAD symptomatology at the beginning and at the end of the program. Pre- and post-treatment
scores were compared and the magnitude of treatment effect was quantified as well based once on
the intention-to-treat (ITT) and once among the completers only. We also examined baseline
predictors of the CBT outcomes.
Results: Seven patients (12%) did not complete the program. For the ITT sample, the percentage
of reduction was 20% to 30% and the pre to post treatment effect sizes ranged from 0.37 to 1.01.
Among the completers, the respective figures were 20% to 33% and 0.41 to 1.19. We found no
significant pretreatment predictor of the outcomes.
Conclusion: Group CBT for SAD is acceptable and can bring about a similar degree of symptom
reduction among Japanese patients with SAD as among Western patients.
Background
Social anxiety disorder, with life time prevalence over
10% [1], is said to be the most prevalent anxiety disorder
in some Western countries. Curiously enough, the
reported prevalence of SAD is much lower in East Asian
countries and East African countries, where it or related
disorders have been believed to be culture-bound [2]. In
order to understand this important disorder, Clark and
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cognitive models that focus on its maintenance mecha-
nisms. In the treatment of SAD, a number of studies have
provided strong evidence for the use of cognitive behavior
therapy (CBT). Five meta-analyses have found large effect
sizes ranging from 0.80 to 1.07 for the reduction of social
anxiety symptoms [5-8]. Moreover, some researchers also
demonstrated that group administered CBT is cost-effec-
tive [6] and is associated with lower relapse rates during
follow-up period than phenelzine [9]. Recent researches
based on the model of Clark and Wells [3] have shown
superior outcomes and the effect sizes of the CBT group
were substantially larger than those reported by other
research groups, suggesting that these new methods are
superior to other CBT programs [10,11].
However, all of these previous reports were mostly from
Europe and North America. Cultural factors are especially
relevant [12,2]. For example, Taijin-Kyofu-Sho (TKS),
which is listed in the appendix to DSM-IV, is said to be a
culture-bound syndrome unique to East Asia. Moreover,
CBT models and treatment components for SAD were
mostly developed in Western cultures with theoretical ori-
entations typically constrained by Western conceptualiza-
tions of anxiety. Translations and modifications are
needed when a treatment program is introduced to Japan
to make it appropriate to the Japanese culture. To date, it
is still unknown whether Western psychological therapies
are effective and acceptable for patients with SAD and
related disorders in non-Western cultures. In addition,
most of the reported studies have been conducted in
research settings and thus do not reflect usual patient sam-
ples in clinical settings. Whether the treatment can be
delivered with the same effectiveness in a more 'naturalis-
tic' medical routine remains unproven. Taken together, it
is necessary to investigate whether CBT can achieve com-
parable treatment outcomes for SAD in non-Western cul-
tures.
The present pilot study aims to report the preliminary out-
comes of the CBT program for SAD at Department of Psy-
chiatry at Nagoya City University Hospital and to examine
the baseline predictors of the outcomes of Japanese
patients with SAD receiving CBT.
Nagoya City University Hospital is located in Nagoya
City, Japan, and is affiliated with the Nagoya City Univer-
sity School of Medicine. It has both inpatient and outpa-
tient sections. In the outpatient section, CBT program for
SAD as well as other anxiety and mood disorders are car-
ried out as a part of routine clinical work.
Methods
Subjects
Fifty seven consecutive patients with SAD were recruited
into the outpatient group-based CBT program at the
Department of Psychiatry, Nagoya City University Hospi-
tal, Japan between July 2003 and January 2007. Some
patients were referred from mental health professionals
and others sought treatment for social anxiety disorder on
their own.
All patients were diagnosed with SAD as the primary dis-
order according to the DSM-IV criteria, as assessed by the
Structured Clinical Interview for DSM-IV [13]. In addi-
tion, all patients fulfilled the following criteria: (a)
absence of a history of psychosis or bipolar disorder, and
of current substance use disorder; and (b) no previous
CBT treatments, nor any other additional psychosocial
therapies during the treatment, and (c) absence of Cluster
B personality disorder. With the exception of criterion (c),
current Axis I major depressive disorder, other current
anxiety disorders and Axis II personality disorders were
not a reason for exclusion if the patients' symptoms
abated enough to allow them to attend the group CBT ses-
sions regularly.
The patients provided their written informed consent after
full explanation of the objectives and procedures of the
present study. The study's protocol was approved by the
Ethics Committee of Nagoya City University Graduate
School of Medical Sciences.
Treatments
Initially we started the program with 12 two-hour ses-
sions, adopting the model developed by Gavin Andrews et
al.[14] in Sydney, Australia. As we modified and
improved the program according to Clark & Wells' model
[3], the program was extended to 12 or more sessions
depending on each group's needs. After this modification,
the average number of sessions per group was 15 (range:
11 to 20).
The program is based on Clark & Wells' model, which
focuses on the maintenance of SAD. The main compo-
nents include 1) psychoeducation regarding the nature of
anxiety and symptoms of SAD, 2) deriving an individual-
ized version of the cognitive-behavioral model of SAD
using patient's own thoughts, images, anxiety symptoms,
safety behaviors and strategies of attention, 3) experiment
to drop safety behaviors and self-focused attention, 4)
attention training to shift focus of attention externally to
the task at hand or the social situation, 5) video feedback
of role-plays of moderately anxiety-provoking situations
to modify distorted self-imagery, 6) behavioral experi-
ments to test the patients' catastrophic predictions during
planned exposure to the situations in within-session role-Page 2 of 10
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tive restructuring for identifying and modifying dysfunc-
tional assumptions especially during behavioral
experiments. Homework was assigned after every session.
The patients were treated in groups of 3 or 4 led by two
therapists (one principal therapist and one co-therapist).
This format was adopted because we found it was too dif-
ficult to provide each one out of four or more patients
with the individual attention that is needed for the
detailed practices of CBT techniques. Most of the patients
appeared to be comfortable with this format. Eight thera-
pists (five psychiatrists and three doctoral-level clinical
psychologists) with more than three years of clinical prac-
tice and experience in treatment of anxiety disorders con-
ducted the treatment program guided by a therapist
manual in Japanese. During the treatment, therapists had
group discussion once a month to check adherence to the
program and to plan for future sessions. However, the
quality of treatment delivery was not rated though audio
or video recordings.
During the CBT treatment, co-administration of antide-
pressants and benzodiazepines was allowed because there
is no evidence to contraindicate their concurrent use
[15,16], and also because symptoms of other comorbid
anxiety and/or depressive disorders had to be controlled
with antidepressants.
Assessment
Patients were assessed with a structured diagnostic inter-
view as well as an extensive questionnaire battery. At base-
line, before treatment commencement, the principal
therapist in charge of the CBT group administered the
mood and anxiety disorder sections of the Structured
Clinical Interview for DSM-IV [13], in order to ascertain
SAD diagnosis and any mood and anxiety comorbidities.
In addition, eight self-reported and one clinician-admin-
istered questionnaires to measure various aspects of SAD
symptomatology and functional impairment, broader
psychopathology in general, and premorbid personality
were administered at the same time. The same instru-
ments, except for the personality inventory, were repeated
at the end of the program.
Social Phobia Scale and Social Interaction Anxiety (SPS/SIAS)
The SPS/SIAS [17] is a 20-item self-report questionnaire
respectively. The SPS was designed to measure the fear of
being observed whereas the SIAS provides a measure of
fear of social interaction. Each scale has twenty items rated
on a 4-point scale, from 0 (not at all characteristic or true
of me) to 4 (extremely characteristic or true of me), with
scores for each scale ranging from 0 to 80. Excellent inter-
nal consistency reliability and sufficient discriminant, pre-
dictive and concurrent validity have been demonstrated
for both of the Japanese versions [18].
Fear Questionnaire – social phobia subscale (FQ-sp)
The FQ-sp is a 5-item self-reported instrument for measur-
ing the fear-motivated avoidance of being observed, per-
forming, being criticized, and talking to authorities [19].
Items are rated on a 9-point Liker-type scale, from 0
(would not avoid it) to 8 (always avoid it). Good test-
retest reliability and factor validity have been demon-
strated [19,20].
The Fear of Negative Evaluation Scale (FNE) and Brief Fear of 
Negative Evaluation Scale (BFNE)
The FNE is a 30-item questionnaire developed to measure
fear of negative evaluation in social situations [21]. Items
are rated as true or false, with the total score ranging from
0 to 30. Good reliability and validity of the Japanese ver-
sion have been reported [22]. However, the newer brief
version of the FNE contains 12 items with a 5-point Likert-
type format (1 = "not at all characteristic of me"; 5 =
"extremely characteristic of me") has been found to be
more sensitive to treatment-related change [23]. We there-
fore switched to BFNE after several groups. As the BFNE
was not given to patients from the beginning, calculations
can only be made for a smaller sample of n = 37 (FNE)
and n = 26 (BFNE).
The Liebowitz Social Anxiety Scale (LSAS)
The LSAS is the most frequently used clinician-adminis-
tered instrument for the assessment of social phobia. It is
a 24-item scale that provides separate scores for fear (0–3
indicate none, mild, moderate, and severe, respectively)
and avoidance (0–3 indicate never, occasionally, often,
and usually, respectively) of social interaction and per-
formance situations, thus providing scores of four sub-
scales, Fear of Performance, Avoidance of Performance,
Fear of Social Interaction, and Avoidance of Social Inter-
action. The Cronbach's alpha reliability estimate of the
Japanese version is 0.95 for total items and 0.80–0.91 for
subscales. In addition, sufficient validity data have also
been provided [24].
Symptom Checklist-90-Revised (SCL-90-R)
The SCL-90-R is a 90-item questionnaire widely used for
the assessment of general psychopathology [25]. It yields
scores for nine primary symptom dimension of somatiza-
tion, obsessive-compulsive, interpersonal sensitivity,
depression, anxiety, hostility, phobic anxiety, paranoid
ideation, and psychosis. The reliability and validity of the
Japanese version have been reported [26].Page 3 of 10
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(WHLS)
The WHLS is a self-report scale for measuring functional
impairments in the areas of work, home management,
social and private activities [19]. The patients' answers are
graded between 0 (not at all impaired) to 8 (very severely
impaired). Satisfactory reliability and construct validity
have been reported [27].
NEO Five Factor Index (NEO-FFI)
This is a 60-item self-reported questionnaire designed to
measure the five major personality dimensions of neurot-
icism, extraversion, conscientiousness, openness and
agreeableness [28]. The Japanese version has been tested
in a general population and satisfactory internal consist-
ency (coefficient alpha) is provided as well as validity
[29].
Statistical analyses
First, treatment completers were compared with patients
dropping out during treatment using unpaired t tests for
continuous variables or chi-squared tests for categorical
variables.
Second, the outcomes of the CBT program for the Japa-
nese patients with SAD were quantified in the following
ways. Our primary outcome was the total LSAS score, and
percentages of patients with symptomatic response and
remission were calculated. Following Bandelow et al.[30],
treatment responder status is defined as 31% or greater
reduction in the LSAS and remission as a score of 36 or
less on the LSAS.
Furthermore, to examine the outcomes of the CBT pro-
gram across various aspects of the disorder, pre- and post-
treatment scores were compared for each SAD symptoma-
tological scale (SPS, SIAS, FQ-sp, FNE, BFNE, LSAS) as
well as the functional scale (WHLS) using paired t tests.
The magnitude of treatment effect was quantified in two
ways by way of the percentage of reduction ((pre – post-
treatment)/pretreatment scores × 100) as well as the effect
size ((Mpretest-Mposttest)/SDpretest). According to Cohen [31],
effect sizes are categorized as follows: small (0.20–0.49),
medium (0.50–0.79), and large effects (0.80 and above).
All statistical analyses for these treatment outcomes were
conducted twice, once based on the intention-to-treat
(ITT) principle whereby all the dropouts were considered
to be non-responders and their last available observations
were carried forward, and once among the completers
only. Treatment completers were defined as participants
who had attended at least 80 percent of the treatment ses-
sions and returned post treatment questionnaires. The ITT
analyses present the more conservative estimates of treat-
ment effectiveness.
Third, in order to elucidate the baseline predictors of the
treatment outcomes, multiple regression analyses were
conducted with the post-treatment LSAS score as a
dependent variable and the baseline demographic and
clinical variables as independent variables, while control-
ling for the baseline LSAS scores. These analyses were per-
formed among the completers only.
All the statistical tests were two-tailed, and an alpha value
of less than 0.05 was considered statistically significant.
All the data were examined using SPSS 15.0 for Windows
[SPSS Inc., 2007].
Results
Demographic and Diagnostic Characteristics of the 
Patients
Table 1 summarizes the demographic and clinical charac-
teristics of patients. All participants met the principal
diagnostic criteria for DSM-IV SAD. Additional Axis I diag-
noses for the patients included other anxiety disorders
(14%), dysthymia (19.3%), and major depressive disor-
der (38.6%).
Comparison of Treatment Completers and Dropouts
Of the 57 patients who agreed to undergo treatment, 7
(12.3%) dropped out before program completion. The
following reasons were given for dropping out: (a) the
therapy seemed too difficult to pursue (n = 1), (b) organ-
izational difficulties due to changes in life styles (e.g.
move back home and too far to come, started working) (n
= 2), (c) there was improvement in symptoms due to the
Table 1: Demographic and clinical characteristics of the patients
Age (years), Mean (SD) 30.4 (10.3)
Age of onset (years), Mean (SD) 17.3 (6.2)
Duration of SAD (years), Mean (SD) 13.3 (10.4)
Gender
Male, n (%) 28 (49.1)
Female, n (%) 29 (50.9)
Marital status
Single, n (%) 40 (70.2)
Married, n (%) 16 (28.1)
Divorced, n (%) 1 (1.7)
Education
University, n (%) 24 (42.9)
College, n (%) 11 (19.6)
High school, n (%) 21 (37.5)
Subtype
Generalized, n (%) 46 (80.7)
Comorbidity
With comorbidity, n (%) 34 (59.6)
Without comorbidity, n (%) 23 (40.4)
Medication
Benzodiazepine (BZ), n (%) 14 (24.6)
Antidepressant (AD), n (%) 28 (49.1)
Both BZ & AD use, n (%) 33 (57.9)Page 4 of 10
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A comparison of demographic and pretreatment variables
in the questionnaires revealed no significant differences
between dropouts and treatment completers (all p values
> 0.10).
Percentage of Patients with Symptomatic Response and 
Remission
For the ITT sample, the mean number of sessions attended
were 14.0 (SD= 4.3), while 15.3 (SD = 2.5) for completers
(n = 50). Nineteen (33.3%) patients were judged to be
responders and 10 (18.5%) of the patients met criterion
for remission at post treatment on the ITT basis including
dropouts. The respective figures were 38.0% and 21.3%
among the completers.
Changes in Symptoms and Functions through the 
Treatment
Table 2 shows the means and standard deviations of all
the measures for all the participants (intention-to-treat)
and completers at pre- and post-treatment.
Examination of change in symptom measures (the LSAS,
SPS, SIAS, FQ-sp, FNE, BFNE) and functional impairment
scale (the WHLS) between pre and post-treatment
revealed significant improvements, not only for the ITT
sample but also for the completers (all p values < 0.01).
Next, the percentage of reduction and effect size in each
symptom measures was calculated and the results are pre-
sented in Table 3.
Table 2: Intention-to-treat and completers mean symptom scores and standard deviations at pre- and post-treatment
Intention-to-treat (n = 57) Completers (n = 50)
Pre Post Pre Post
Social Phobia Scale 36.2 (15.4) 24.7 (15.2) *** 36.7 (15.4) 24.0 (15.3) ***
Social Interaction Anxiety Scale 54.8 (15.0) 43.0 (16.0) *** 54.9 (14.8) 41.8 (15.6) ***
Fear of Negative Evaluation1 24.6 (5.1) 22.1 (6.5) ** 24.3 (5.1) 20.8 (6.5) **
Brief Fear of Negative Evaluation2 33.2 (10.7) 28.1 (9.6) ** 33.4 (10.6) 27.6 (9.3) ***
FQ-spa 24.0 (6.2) 17.8 (7.8) *** 24.2 (6.2) 16.9 (8.1) ***
WHLSb 14.0 (6.1) 10.4 (6.3) *** 13.9 (6.1) 9.4 (6.3) ***
LSAS (total)c 76.2 (25.6) 59.6 (27.3) *** 77.2 (26.1) 58.5 (27.8) ***
Fear of performance 20.8 (5.8) 16.3 (6.9) *** 20.9 (6.1) 15.9 (7.2) ***
Avoidance of performance 17.3 (8.2) 11.5 (7.9) *** 17.8 (8.3) 11.1 (8.0) ***
Fear of social interaction 20.0 (6.9) 17.5 (7.2) ** 20.1 (6.8) 17.3 (7.2) **
Avoidance of social interaction 18.1 (7.9) 14.3 (8.5) *** 18.4 (7.8) 14.2 (8.4) ***
NEO Five Factor Index
Neuroticism 31.0 (9.0) - 31.6 (9.2) -
Extroversion 21.8 (8.0) - 21.6 (8.1) -
Conscientiousness 24.7 (7.7) - 24.6 (8.0) -
Openness 30.5 (6.7) - 29.0 (5.3) -
Agreeableness 24.2 (7.9) - 30.3 (6.8) -
Symptom Checklist-90 Revised
Somatization 0.7 (0.6) 0.5 (0.6) n.s. 0.7 (0.6) 0.5 (0.5) **
Obsessive-compulsive 1.7 (0.9) 1.4 (0.9) ** 1.7 (0.9) 1.3 (0.8) **
Interpersonal sensitivity 2.1 (0.8) 1.6 (0.9) *** 2.1 (0.8) 1.4 (0.9) ***
Depression 1.6 (0.8) 1.2 (0.9) *** 1.6 (0.8) 1.1 (0.8) ***
Anxiety 1.5 (0.8) 1.2 (0.9) ** 1.4 (0.8) 1.1 (0.9) **
Hostility 0.8 (0.6) 0.6 (0.6) ** 0.8 (0.6) 0.6 (0.6) **
Phobic anxiety 1.1 (0.8) 0.7 (0.7) *** 1.1 (0.8) 0.7 (0.6) ***
Paranoid ideation 1.1 (0.8) 0.8 (0.9) ** 1.1 (0.7) 0.8 (0.8) **
Psychoticism 0.8 (0.5) 0.6 (0.6) *** 0.9 (0.5) 0.6 (0.6) ***
FQ-spa: Fear Questionnaire Social Phobia Subscale
WHLSb: Work, Home and Leisure Activities Scale
LSAS (total)c: Liebowitz Social Anxiety Scale (total)
Fear of Negative Evaluation1: Number for ITT = 37, Number for Completers' analysis = 27
Brief Fear of Negative Evaluation2: Number for ITT = 26, Number for Completers' analysis = 23 
(*** p < 0.001, **p < 0.01)Page 5 of 10
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tion was 20% to 30% for most of the symptom measures
and 20% for WHLS. However, a lower improvement in
FNE (9%), BFNE (12%) and fear of social interaction sub-
scale of LSAS (10%) were seen for all the participants.
Furthermore, based on the analyses of ITT sample, effect
size for the social phobic measures (SPS, SIAS, FNE, BFNE,
FQ-sp, and LSAS total and subscale scores) at post assess-
ment ranged from 0.37 to 1.01 and was 0.59 on WHLS
(see Table 3). According to Cohen's classification [31],
FQ-sp displayed largest effects whereas the other social
phobic measures showed moderate effects at best. Moreo-
ver, FNE, BFNE, Fear of social Interaction subscale and
Avoidance of Social Interaction subscale of LSAS were
associated with a small effect sizes at post treatment.
Similar to the ITT sample, completer analyses indicated a
20% to 33% percentage of reduction for most of the
symptom measures and 36% for the WHLS. A lower per-
centage of reduction was also seen in FNE (12%) and fear
of social interaction subscale of LSAS (11%).
For treatment completers, effect sizes at post assessment
ranged from 0.41 to 1.19 on the social phobic measures
which indicated a greater change than the ITT sample.
Among the outcome variables, not only FQ-sp, but also
SIAS, SPS, Fear of performance subscale and Avoidance of
performance subscale of LSAS displayed large effect sizes.
In addition, effect size of WHLS was 0.75.
Predictors of Treatment Response
Multiple regression analyses, using the baseline LSAS
score and each demographic variable (age, gender, marital
status, educational status, age of onset, duration of disor-
der, subtypes, presence of comorbid, use of anxiolytic
medication, or use of antidepressant medication, number
of treatment sessions) as independent variables and the
post treatment LSAS score as a dependent valuable, were
conducted. None of the variables were significant predic-
tors of post treatment LSAS score.
The last analysis addressed the predictive relationship
between NEO and SCL pretreatment scores and post treat-
ment LSAS score. We carried out two separate, multiple
linear regression analyses with the five subscales of NEO
and the nine subscales of SCL-90-R as the respective
explanatory variables, and the post treatment LSAS score
as the dependent variable, while controlling the pretreat-
ment LSAS score. However, neither NEO nor SCL-90-R
appeared as a predictor in these analyses.
Discussion
Firstly, the present study demonstrated that a CBT pro-
gram for SAD, originally developed in Western countries,
is feasible and effective in a Japanese clinical setting. To
date, cultural impact is said to be relevant to the preva-
lence, presentation, and treatment of SAD [2]. In Japan,
for example, TKS is said to be a Japanese conceptualiza-
tion of SAD. Although TKS and SAD are both character-
ized by excessive fear and avoidance of social interaction
and performance, the concerns in TKS center on offending
or embarrassing others [32]. Despite a better understand-
ing of the variation in symptom presentation of some of
the trans-cultural variants of SAD, such as TKS, little is
known about the usefulness of Western psychological
therapies for it. In addition, various methodological
explanations can be offered to explain cross-cultural dif-
Table 3: Percentage of reduction and effect size for symptom scales (Intention-to-treat and completers)
Intention-to-treat Completers
% of reduction Effect size % of reduction Effect size
Social Phobia Scale 30 0.75 33 0.83
Social Interaction Anxiety Scale 21 0.79 23 0.89
Fear of Negative Evaluation 9 0.49 12 0.68
Brief Fear of Negative Evaluation 12 0.48 20 0.54
FQ-spa 25 1.01 30 1.19
Liebowitz Social Anxiety Scale (total) 20 0.65 22 0.71
Fear of performance 21 0.78 23 0.83
Avoidance of performance 26 0.71 31 0.80
Fear of social interaction 10 0.37 11 0.41
Avoidance of social interaction 20 0.47 23 0.53
WHLSb 20 0.59 36 0.75
FQ-spa: Fear Questionnaire Social Phobia Subscale
WHLSb: Work, Home and Leisure Activities ScalePage 6 of 10
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not only the use of assessment instruments but the treat-
ment components which were developed in English and
translated into Japanese may affect the outcome of CBT
program. Therefore, it is necessary to investigate whether
an equal treatment outcome can be achieved when trans-
porting the Western developed CBT to Japan. Irrespective
of cultural background, our results suggested that the CBT
program appears to be equally acceptable to Japanese
patients with SAD as to Western patients, because our
dropout rate (12.3%) is generally lower than those
reported in Western studies of group CBT (see Table 4)
and comparable to some individual CBT programs
[33,34].
In terms of effectiveness, our CBT program also compares
favorably with Western reports. For example, our group
CBT program was able to reduce most of the symptom
measures by 20 to 30%, figures comparable to those
reported in Western settings [33-35]. Several previous
meta-analyses of CBT for SAD have derived effect sizes
based on within-group change from pre to post treatment
between 0.51 to 1.06 for completers [5,7,8]. Within-group
effect sizes in our program were largely consistent with
these figures (see Table 3). However, effect sizes reported
in the previous studies were calculated by various meth-
ods from various outcome measures. For a direct compar-
ison with studies of group CBT conducted recently using
similar SAD symptomatological scales, we calculated the
effect sizes based on these scales using the formula Mpre-
test-Mposttest/SDpretest. As shown in Table 4, our pre to post
treatment effect sizes were superior to those of the previ-
ous studies of group CBT with regard to FQ-sp, SPS, SIAS,
and subscales of LSAS (Fear of performance, Avoidance of
performance, Avoidance of social interaction). However,
two recent RCTs demonstrated superiority of individual
format CBT over group format [33,34]. Our program was
carried out in groups of only 3 to 4 patients in order to
allow as much individual attention as possible while
retaining the advantage of group settings (e.g. role plays
and learning through peers) and therefore can be thought
to be more individualized than most reported group CBT
programs (6–8 patients per group, and fixed sessions).
However, the existence of a similar advantage of strictly
individual format among Japanese patients has yet to be
investigated.
Moderate effect sizes were demonstrated for WHLS, indi-
cating that the impact of SAD on patients' daily lives had
reduced. However, there are very few studies that used
WHLS as an outcome measure, so that a direct compari-
son was not possible here. Similarly, a direct comparison
Table 4: Comparison of effect sizes by group CBT
Completers analyses ITT
Study Heimberg (1998) Stangier (2003) Present study Mörtberg (2007) Present study
Group 12 weeks 15 weeks 16 weeks 3 weeks 16 weeks
N 36 26 57 35 57
Drop out (%) 22.2 15.4 12.3 25.7 12.3
Pre Post ES Pre Post ES Pre Post ES Pre Post ES Pre Post ES
LSAS total 59.0 46.2 0.97 77.2 58.5 0.71 68.1 52.5 0.75 76.2 59.6 0.65
SD 13.2 8.9 26.1 27.8 20.9 19.4 25.6 27.3
Social fear 15.1 12.0 0.44 20.1 17.3 0.41 20.0 17.5 0.37
SD 7.0 4.9 6.8 7.2 6.9 7.2
Social avoidance 13.1 9.9 0.42 18.4 14.2 0.53 18.1 14.3 0.47
SD 7.7 4.8 7.8 8.5 7.9 8.5
Performance fear 17.0 13.4 0.65 20.9 15.9 0.83 20.8 16.3 0.78
SD 5.6 3.8 6.1 7.2 5.8 6.9
Performance avoidance 13.8 10.9 0.47 17.2 11.1 0.80 17.3 11.5 0.71
SD 6.0 4.3 8.3 8.0 8.2 7.9
FQ-spa 19.0 14.7 0.60 24.2 16.9 1.19 20.7 15.5 0.78 24.0 17.8 1.01
SD 7.2 4.0 6.2 8.1 6.7 7.1 6.2 7.8
SPS 27.3 25.8 0.09 33.6 25.5 0.53 36.7 24.0 0.83 36.5 27.7 0.64 36.2 24.7 0.75
SD 17.0 10.0 15.3 15.3 15.4 15.3 13.8 11.5 15.4 15.2
SIAS 41.8 39.4 0.13 45.8 38.4 0.53 54.9 41.8 0.89 44.5 36.7 0.48 54.8 43.0 0.79
SD 18.4 13.2 14.0 12.4 14.8 15.6 16.1 14.7 15.0 16.0
FNE 22.3 21.4 0.12 24.3 20.8 0.68 22.5 21.5 0.15 24.6 22.1 0.49
SD 7.6 4.3 5.2 6.5 6.5 7.2 5.1 6.5
FQ-spa: Fear Questionnaire Social Phobia SubscalePage 7 of 10
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possible because of imprecise description in many of the
studies.
In addition to the outcomes described previously, we con-
ducted a preliminary examination on whether there are
any differences between patients with SAD and TKS. Six
patients (10.5%) met the criteria of TKS and there were no
statistical and substantial differences between patients
with SAD and TKS in terms of LSAS, SPS or SIAS both
before and after the treatment (For TKS, the means (SD)
of LSAS, SPS and SIAS were 75.5 (43.5), 35.3 (17.4), 45.8
(19.1) at baseline, and 61.3 (49.9), 33.8 (21.8) and 43.0
(24.0) at end of treatment).
Secondly, identifying possible predictors of treatment
response in the treatment completers showed that none of
the pretreatment variables were significant predictors of
scores of LSAS at post treatment. A number of studies have
examined the role of particular variables in predicting
response to treatment and their influence on overall ther-
apeutic outcome but the results were inconsistent and
inconclusive [36]. The fact that no predicting effect
emerged indicates that pretreatment variables may have
little to offer for the prediction of treatment outcome.
However, there are some other variables we did not
directly measure in our study. For example, expectancy for
improvement is said to be related to outcome [36]. Future
studies should also focus not only on pretreatment varia-
bles but also processes during the treatment, such as
homework compliance and the client-therapist relation-
ship which was suggested by Scholing et al.[37].
The present study has several limitations. First, this is a
preliminary study which was conducted in a Japanese rou-
tine clinical setting. As we modified and improved the
treatment program based on the latest theoretical model,
it may raise a problem of treatment consistency. A further
study should examine whether there are differences in
treatment outcome due to different CBT models. Moreo-
ver, lack of supervision may also have decreased treatment
consistency and adherence to treatment. In Japan, there
are not enough professional therapists for CBT available
in routine medical settings. Regular supervision from
experts in cognitive therapy is necessary and will further
strengthen the training system.
Second, it must be pointed out that in the present study
the principle therapist conducted the diagnostic assess-
ments before and after the treatment, which may cause
detection bias as well as performance bias. Independent
blind assessor ratings would have strengthened our con-
clusions. Moreover, repeated t-test for comparing pre-
treatment with post-treatment scores may have increased
the risk of Type I error. Thus, some non-important differ-
ences may have been falsely found to be statistically sig-
nificant. However, the magnitude of treatment effect was
quantified by effect size as well as the percentage of reduc-
tion and the results are clearly demonstrated.
Third, the inclusion of subjects using psychotropic medi-
cation, although increasing the generalizability of the
study, also confounds the treatment results because ethi-
cally we could not prohibit medication changes while
subjects participated in the study. However, previous
researches have failed to find a significant advantage for
combined pharmacotherapy and CBT [10,15,16]. Rosser
et al.[38] investigated the impact of preexisting antide-
pressant use on the outcome of group CBT for SAD in a
naturalistic routine clinical setting and also failed to find
a significant difference between combined treatments and
CBT alone. In our study, none of the pretreatment varia-
bles were significant predictors of scores of LSAS at post
treatment suggested that medication may have little
impact on the treatment outcome. Furthermore, for those
25 (50%) patients who completed the treatment and who
had already been on medication upon study participa-
tion, we examined the medication regimen at the end of
treatment. Twelve (25%) of them were stabilized on the
regimen throughout the treatment, while 8 (16%) had
their medication reduced, and 3 (6%) had it increased. No
data was available for two of the patients because they had
their prescription filled elsewhere. In other words, over
90% of the subjects had their medication status
unchanged or decreased through the study.
Nevertheless, considering that antidepressant medication
and benzodiazepines are effective for the treatment of
SAD [15], the current study did not answer questions as to
whether the treatment outcome is due to the contribution
of medication or CBT alone. Future controlled trials need
to explore the issue whether pre-existing medication has a
significant impact on treatment outcome and also to
address the question of whether treatment effects are
maintained over the longer term to an equivalent extent
for CBT alone, pharmacotherapy alone, or a combined
approach.
Fourth, our sample size was relatively small and thus
power was limited, especially with regard to predictive
variables. Moreover, lack of control group data limits the
generalizability of the results and lack of follow-up data
limits the ability of the study to comment on longer term
outcomes. Future studies including larger sample and
control group should provide more insight into the CBT
treatment in Japanese routine medical settings.
Despite the limitations, this pilot study provided an inde-
pendent CBT treatment within a routine psychiatric serv-
ice in a different cultural setting from the WesternPage 8 of 10
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Japan in comparison with those from Western countries.
Although there is still room for improvement, our results
suggested a general replication of CBT for SAD in Japan.
Conclusion
CBT program for SAD, originally developed in Western
countries, is acceptable to Japanese patients in a routine
clinical setting. Within-group changes from pre to post
treatment obtained by group CBT program are compara-
ble to those reported in Western settings.
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